Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9BZV3: Variant p.Cys1077Phe

Interphotoreceptor matrix proteoglycan 2
Gene: IMPG2
Feedback?
Variant information Variant position: help 1077 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Phenylalanine (F) at position 1077 (C1077F, p.Cys1077Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In VMD5. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1077 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1241 The length of the canonical sequence.
Location on the sequence: help QPDFCLNDGKCDIMPGHGAI C RCRVGENWWYRGKHCEEFVS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         QPDFCLNDGKCDIMPGHGAICRCRVGENWWYRGKHCEEFVS

Mouse                         QPDFCLNDGKCDIMPGHGAICRCRVGSNWWYRGQHCEEFVS

Rat                           QPDFCLNDGKCDVMPGHGAICRCRVGSNWWYRGQHCEEFVS

Chicken                       QPNFCLNDGKCDISPGQGAICRCRVGENWWYRGEHCEEYVS
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 23 – 1241 Interphotoreceptor matrix proteoglycan 2
Topological domain 23 – 1099 Extracellular
Domain 1052 – 1093 EGF-like 2
Disulfide bond 1061 – 1077



Literature citations
Frequency and clinical pattern of vitelliform macular dystrophy caused by mutations of interphotoreceptor matrix IMPG1 and IMPG2 genes.
Meunier I.; Manes G.; Bocquet B.; Marquette V.; Baudoin C.; Puech B.; Defoort-Dhellemmes S.; Audo I.; Verdet R.; Arndt C.; Zanlonghi X.; Le Meur G.; Dhaenens C.M.; Hamel C.P.;
Ophthalmology 121:2406-2414(2014)
Cited for: INVOLVEMENT IN VMD5; VARIANT VMD5 PHE-1077; Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions.
Brandl C.; Schulz H.L.; Charbel Issa P.; Birtel J.; Bergholz R.; Lange C.; Dahlke C.; Zobor D.; Weber B.H.F.; Stoehr H.;
Genes (Basel) 8:0-0(2017)
Cited for: VARIANTS VMD5 226-GLU--VAL-1241 DEL; 522-SER--VAL-1241 DEL; 856-GLN--VAL-1241 DEL AND PHE-1077; VARIANTS PRO-243; ASP-1008; SER-1016 AND CYS-1042;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.